Clinical Trials Details

S1800D LUNGMAP - SUBSTUDY (Lung)

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stave IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 Therapy (LUNGMAP Non-Match Substudy)

Objective

Key eligibility: Progressed on most recent line of treatment for NSCLC; must have received one line of anti-PD-1 or anti-PD-L1 therapy for advanced disease. 

» Learn more about this trial

Clinical Trial Categories

  • Cancers and Other Neoplasms